ASCRS Eyeworld

EyeWorld.org

OphthalmologyBusiness.org

The news magazine of the American Society of

Click

Issue

to read

September

September 2016 Digital Edition

AAO city preview — P. 58 Intracorneal ring segment use — P. 72 Tracking and avoiding IOL errors — P. 112



Crosslinking considerations

Featuring: Corneal collagen crosslinking

Incorporating the procedure into practice — P. 78

Epi-off vs. epi-on debate continues — P. 80 Corneal crosslinking's refractive possibilities — P. 84

Deciding when to use crosslinking — P. 86 Crosslinking in new therapeutic areas — P. 88



EyeWorld Education Hub

In this issue: Corneal collagen crosslinking

Incorporating the procedure into practice — P. 78

Epi-off vs. epi-on debate continues — P. 80

Corneal crosslinking's refractive possibilities — P. 84

Deciding when to use crosslinking — P. 86

Crosslinking in new therapeutic areas — P. 88

AAO city preview — P. 58

Intracorneal ring segment use — P. 72

Tracking and avoiding IOL errors — P. 112



Click to view CME Supplement

EducationHub.EyeWorld.org

Now Online from EyeWorld CME Symposia at ASCRS: Astigmatism Management & Toric IOLs: The Path to Surgical Success with Preoperative Measures with Advanced Diagnostic Tools



Table of contents P. 4, 6, 8

Fixing a toric IOL that has dislocated into vitreous cavity after retina surgery — P. 40 AAO city preview — P. 58 Intracorneal ring segment use — P. 72 Tracking and avoiding IOL errors — P. 112



VOLUME 21, NUMBER September 2016

The news magazine of the American Society of Cataract & Refractive Surgery

Crosslinking considerations

Featuring: Corneal collagen crosslinking

Incorporating the procedure into practice — P. 78

Epi-off vs. epi-on debate continues — P. 80 Corneal crosslinking's refractive possibilities

— P. 84

Deciding when to use crosslinking — P. 86 Crosslinking in new therapeutic areas — P. 88



Table of contents P. 4, 6, 8



Fixing a toric IOL that has dislocated into vitreous cavity after retina surgery - P. 40 September 2016

Refractive editor's corner of the world



e are in an era of rapid innovation in corneal refractive surgery, and the last 12 months have given us a wide range of technologies that provide more options to improve the outcomes for our patients. One particularly exciting technology is corneal crosslinking, and specifically its use in therapeutic cases. According to the 2016 ASCRS Clinical Survey, almost 20% of ASCRS members plan on performing crosslinking procedures in the next 12 months.

In this month's "Refractive editor's corner of the world," Roberto Pinelli, MD, Anders Behndig, MD, and A. John Kanellopoulos, MD, provide an excellent overview of how this new technology may fit into our practices, in terms of patient selection, protocols, and potential combination treatments. Corneal crosslinking, though available outside of the U.S. for many years now, is a new option for many surgeons. As with any new product, we should continue to review studies and the literature, as well as seek out additional educational resources to ensure we are well versed and equipped to provide the best options for our patients.

Steven Schallhorn, MD,

Refractive editor

Predictable refractive outcomes: The future of keratoconus treatment

by Liz Hillman EyeWorld Staff Writer

Experts say PiXL procedure is promising but still has "a long way to go"

xtremely interesting and positive." That's how **Roberto Pinelli**, **MD**, founder of

the Switzerland Eye Research Institute, Lugano, Switzerland, described the current state of crosslinking in ophthalmology.

While excitement certainly continues after the U.S. Food and Drug Administration (FDA) approval of Photrexa and Photrexa Viscous (Avedro, Waltham, Massachusetts) as well as the company's KXL System for treatment of progressive keratoconus earlier this year, the riboflavin-UV light procedure—first described decades ago and available internationally for years—is not remaining stagnant in its technology or technique. There have been modifications as well as new indications for the procedure in recent years.

Conventional crosslinking stabilizes and strengthens the cornea for progressive keratoconus and ectasia patients, but some physicians have been working with the technology and refining the technique to obtain predictable refractive outcomes as well.

"We know that crosslinking for keratoconus is a very good treatment," **Anders Behndig, MD**, Umeå University, Sweden, said at the 2016 ASCRS•ASOA Symposium & Congress. "We do the same treatment protocol in all cases of keratoconus though, which from a refractive standpoint might not be so good.

"Of course, the main purpose of the treatment is to halt the disease, which [crosslinking] does, but it would be nice to control the refractive effects of the treatments, too," Dr. Behndig continued.

For both refractive effects and corneal stability, crosslinking is now regularly coupled with topography-guided photorefractive keratectomy (PRK), intrastromal rings, and even LASIK. Dr. Behndig thinks there could be another option for predictable refractive outcomes in keratoconus treatment: photorefractive intrastromal crosslinking (PiXL, Avedro). This topography-guided crosslinking, which has been available internationally for the last few years, is marketed by Avedro as the "next revolution in refractive correction" in low myopic or post-cataract patients. Dr. Behndig spoke at the ASCRS•ASOA Symposium & Congress about PiXL in the context of providing customized, refractive keratoconus treatment.

PiXL, which Avedro describes as using "precise, patterned, topography-guided accelerated crosslinking," involves real-time eye tracking and a higher UVA power. The UV light is customized and directed in a specific pattern based on the patient's topography to flatten the cornea where most needed.

According to his own research involving 12 months worth of data on 25+25 eyes, Dr. Behndig said he found that PiXL offered a significant refractive advantage over conventional crosslinking in keratoconus. He admitted, however, that the difference was not huge.

"The effects are promising so far. Of course, the method will need further fine tuning, but my impression is that this procedure has the potential to become valuable in treating keratoconus in the future."

Dr. Pinelli, who patented the transepithelial riboflavin solution ParaCel, now owned by Avedro, has had a similar experience with the technology.

"Obviously the customization based on topography is theoretically interesting, but we have no difference in our cases between the groups with and without controlled procedures in terms of stability of results," Dr. Pinelli said, explaining that he has used PiXL for about 3 months in about 100 cases.

A. John Kanellopoulos, MD, medical director, LaserVision.gr Eye Institute, Athens, who pioneered research with numerous crosslinking techniques, said PiXL has shown some "remarkable excimer-like effects ... without tissue removal, making it a promising treatment for progressive keratoconus, corneal ectasia, and even refractive correction in low myopes, but it has a long way to go."

"PiXL offers a new indication of not only stabilizing the cornea with crosslinking but also being able to, through the predetermined variable pattern and variable fluence, result in a predictable refractive effect," Dr. Kanellopoulos said.

Dr. Kanellopoulos said eventually he thinks this individualized, topography-based crosslinking technique will replace conventional corneal collagen crosslinking as the keratoconus treatment of choice.

"If one has in his armamentarium the availability of PiXL, it automatically becomes the treatment of choice because not only can it stabilize ectasia through its efficacy and safety and introduction of higher corneal rigidity, but it can also through its variable pattern help improve the refractive effect," he said, noting that correction of irregular myopic astigmatism, which is especially linked to keratoconus and post-LASIK ectasia, would be an extreme benefit to patients.

PiXL compared to crosslinking combo procedures

PiXL is not the only procedure that seeks to address refractive error while ensuring a stable cornea. Conventional crosslinking has also been combined with topography-guided PRK, intrastromal rings, and LASIK.

Dr. Kanellopoulos said that while traditional crosslinking in and of itself can result in a 1.5–2 D correction of irregular astigmatism and flattening, when performed after PRK—the Athens protocol physicians can achieve up to 15 D of correction.

Dr. Pinelli said that when refractive error of up to 2 D remains after transepithelial crosslinking (also known as epi-on crosslinking where the epithelium is not removed prior to soaking the cornea with riboflavin as it would be in epi-off procedures), he usually corrects it with an advanced surface ablation technique. For higher diopters of refractive error, Dr. Pinelli said he usually performs intraocular surgery, such as a lensectomy or phakic IOL implant, 3 months post-crosslinking.

Dr. Behndig told *EyeWorld* that the fact that PiXL doesn't remove any tissue might be an advantage, but he acknowledged that PRK may have better refractive precision.

"We don't know which factors make one treatment—PiXL or crosslinking and PRK—better than

Exam	A: A: 06/02/2014 14:53:59 Right (25) 3D-Scan HR	B: 12/15/2014 13:25:52 Right (25) 3D-Scan HR	Difference A - B
90.0 85.0 80.0 75.0 70.0 65.0	90* K1: [44.4 D Astig: [1.7 D . K2 [46:0 D [7/m]] [-0.63 . K2 [flat] [7.8* QS: [0K	90* K1: [43,7 D Astig [0.8 D 5 -	90* K1: +0.7D Astig +0.9D +150
60.0 55.0 50.0 48.0 46.0	Pachy: x[mm] y[mm] Pupil Center: + 513 μm -0.23 +0.09 Thinnest Locat: O 505 μm -0.46 -1.59	Pachy: x(mm) y(mm) Pupil Center: + 503 µm -0.05 +0.10 Thinnest Locat: O 432 µm -0.81 -0.47	Pacty: x[mm] y[mm] 40 Pupil Center: + +9 μm -0.18 0.00 +7.0 Thinnest Locat: O +13 μm +0.35 -1.11 +6.0
45.0 44.0 43.0 42.0	Chamber Volume: 205 mm ³ Angle: 33.1 * A. C. Depth (Int.): 4.31 mm Pupil Dia: 4.68 mm	Chamber Volume: 212 mm ³ Angle: 41.5 * A. C. Depth (Int.): 4.56 mm Pupil Dia: 213 mm	Chamber Volume: -7 mm ³ Angle: -2.4 ⁺ +2.0 A C. Depth (int.): -0.25 mm Pupil Dia: +2.55 mm +1.0
41.0 40.0 39.0	IOP(cor): Lens Th. Axial / Sagital Curvature (Front)	IOP(cor): Lens Th: Axial / Sagital Curvature (Front)	IOP(cor): Lens Th.: 1.0 Axial / Sagital Curvature (Front) Image: Curvature (Front) Image: Curvature (Front)
370 370 360 340 330 320 310 250 150 150 D Curvature	90° OD 90° OD 4 0 OD 4 4 4 8 7	90° OD 90° OD 44 44 0 44 455 432 44 455 432 44 455 432 44 455 432 455 432 455 432 455 432 455 157 157 157 157 157 157 157 1	$\begin{array}{c} & & & & & & & & & & & & & & & & & & &$
Abs	8 4 0 4 8	8 4 0 4 8	8 4 0 4 8 Rel

A 45-year-old male with 2 D myopia received epi-on PiXL treatment. His preop measurements are on the left, postop in the middle, and the difference between the two on the right.

WAVELIGHT - ALLEGRO TOPOLYZER VARIO



These are the difference maps (preop top right, postop bottom right, and preop minus postop left) documenting excimer-like correction with crosslinking alone in a pseudophakic female who achieved 2.5 D of myopic correction with PiXL treatment. Source: A. John Kanellopoulos, MD

the other in the individual case," he said.

Dr. Kanellopoulos said he thinks PiXL could be combined with topography-guided PRK as well for even better refractive outcomes.

"In my mind, any patient with a refractive error resulting from corneal ectasia and keratoconus is a good candidate for the Athens protocol [topography-guided PRK followed by crosslinking]; having PiXL in our hands, we can employ [it] in combination with the partial topography-guided PRK in order to achieve a better refractive correction of the cornea and also being able to remove less tissue and/or being able to apply this even in corneas where no tissue can be removed due to limitations from cornea thinning that go along with ectasia," he said.

Where to go from here

Dr. Kanellopoulos said PiXL is his treatment of choice for patients with corneas too thin to consider an excimer or femtosecond laser procedure and for post-cataract surgery patients left with only a small amount of ametropia. Still, he said more needs to be learned about cornea biomechanics and variability among patients. He also said a dose effect nomogram needs to be developed.

Dr. Pinelli thinks PiXL should be improved when it comes to the time and energy currently required in the procedure.

"Sometimes the treatment is too long; we should stay within the accelerated crosslinking parameters," he said.

Dr. Behndig said more research is needed to optimize treatment parameters of PiXL for both keratoconus and myopia patients. **EW**

Editors' note: Drs. Behndig and Pinelli have no financial interests related to their comments. Dr. Kanellopoulos has financial interests with Alcon (Fort Worth, Texas), Allergan (Dublin), A.R.C. Laser (Nuremberg, Germany), Avedro, KeraMed (Orange, California), Optovue (Fremont, California), and Carl Zeiss Meditec (Jena, Germany).

Contact information

Behndig: anders.behndig@umu.se Kanellopoulos: ajkmd@mac.com Pinelli: pinelli@seri-lugano.ch